Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...
Zacks.com on MSN18h
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...
An Investigation Has Commenced on Behalf of Vertex Pharmaceuticals Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your VRTX Losses.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
10 growth stocks in the S&P 500's bargain sector
The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics today
EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.
US open: Stocks mixed as tech stocks weigh on Nasdaq
Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...